Atara Biotherapeutics, Inc.
ATRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001604464
In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Atara Biotherapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $1.00M in total
- Open-market sells
- 1 filing
- 1 insider, $40.9K in total
- Insiders trading
- 2
- Net value
- +$959.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Atara Biotherapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Cherry Brian N | Director | 166,486 | Sep 4, 2026 | 2 |
| Nguyen AnhCo | President and CEO | 132,775 | Aug 26, 2026 | 5 |
| Redmile Group, LLC | Director | 636,852Indirect | Jul 24, 2026 | 1 |
| Green Jeremy | Director | 636,852Indirect | Jul 24, 2026 | 1 |
| Heiden William K | Director | 34,188 | Jun 11, 2026 | 1 |
| Fust Matthew K | Director | 30,188 | Jun 11, 2026 | 1 |
| Ciongoli Gregory Austin | Director, 10% Owner, Other: See Remarks | 12,000 | Jun 11, 2026 | 1 |
| Grant-Huerta Yanina | Chief Accounting Officer | 49,636 | May 20, 2026 | 4 |
| Huang James | Director, 10% Owner | 1,011,000Indirect | May 11, 2026 | 4 |
| Panacea Innovation Ltd | 10% Owner | 1,011,000Indirect | May 11, 2026 | 4 |
| EcoR1 Capital, LLC | 10% Owner | 1,552,000Indirect | May 11, 2026 | 1 |
| Gallagher Carol Giltner | Director | 33,012 | Jun 12, 2025 | 0 |
| Touchon Pascal | Director | 77,955 | Jun 12, 2025 | 0 |
| Roncarolo Maria Grazia | Director | 17,368 | Jun 12, 2025 | 0 |
| Mallik Ameet | Director | 16,928 | Jun 12, 2025 | 0 |
| Adiumentum Capital Fund I LP | Director, 10% Owner, Other: See remarks | 1,209,395 | May 16, 2025 | 0 |
| Adiumentum Capital Fund I GP LLC | Director, 10% Owner, Other: See remarks | 1,209,395 | May 16, 2025 | 0 |
| Hyllengren Eric J | Other: Former EVP, CFO & COO | 56,231 | Apr 2, 2025 | 0 |
| Henrich Jill | EVP, Chief Regulatory Officer | 18,679 | Mar 5, 2025 | 0 |
| Murugan Amar | EVP, Chief Legal Officer | 26,827 | Aug 20, 2024 | 0 |
| Joshi Manher | EVP, Chief Medical Officer | 171,284 | Nov 20, 2023 | 0 |
| Dobmeier Eric | Director | 563,325 | Nov 14, 2023 | 0 |
| Seidenberg Beth C | Director | 115,689 | Jun 2, 2023 | 0 |
| Banard Charlene A. | EVP, Chief Technical Officer | 276,010 | May 18, 2023 | 0 |
| Dupont Jakob | EVP, Head of R&D | 290,794 | Mar 6, 2023 | 0 |
| Koppikar Utpal | Chief Financial Officer | 181,978 | Mar 6, 2023 | 0 |
| Renaud Ronald C JR | Director | 31,500 | Jun 27, 2022 | 0 |
| Baynes Roy D. | Director | 43,500 | Jun 27, 2022 | 0 |
| Yarema Kristin | Chief Commercial Officer | 171,415 | Mar 3, 2022 | 0 |
| Newell Joe | Chief Operations Officer | 113,097 | Nov 18, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 (view filing)6:20 PM ET | Sep 4 | Same day | Cherry Brian NDirector | PPurchase | +104.2K | $9.60 | +$1.00M | +167.1%166.5K after |